WHO prequalified Novartis’ Coartem Baby, the first malaria treatment specifically developed for newborns and young infants weighing 2 to 5 kilograms. The approval clears a key regulatory hurdle and broadens access to a previously untreated patient segment. The news is positive for Novartis, though the immediate market impact is likely modest.
WHO prequalified Novartis’ Coartem Baby, the first malaria treatment specifically developed for newborns and young infants weighing 2 to 5 kilograms. The approval clears a key regulatory hurdle and broadens access to a previously untreated patient segment. The news is positive for Novartis, though the immediate market impact is likely modest.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
